Nancy E. Denyes - 03 Feb 2026 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Role
General Counsel
Signature
/s/ Nancy E. Denyes
Issuer symbol
ATYR
Transactions as of
03 Feb 2026
Net transactions value
-$1,091
Form type
4
Filing time
04 Feb 2026, 19:12:45 UTC
Previous filing
09 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DENYES NANCY General Counsel 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO /s/ Nancy E. Denyes 04 Feb 2026 0001640869

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATYR Common Stock Options Exercise +2,687 +8.5% 34,242 03 Feb 2026 Direct F1, F2
transaction ATYR Common Stock Sale $1,091 -1,118 -3.3% $0.9761 33,124 04 Feb 2026 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATYR Restricted Stock Unit Options Exercise $0 -2,687 -100% $0.000000 0 03 Feb 2026 Common Stock 2,687 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
F4 The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.